VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Long-term efficacy of first-line ibrutinib for CLL: a pooled analysis from 4 trials

John Allan, MD, Weill Cornell Medicine, New York, NY, outlines the results of a pooled analysis of four clinical trials investigating the long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with a four-year follow-up of patients with TP53 aberrations. The clinical trials included in the analysis were PCYC-1122e (NCT01500733), PCYC-1130 (NCT02264574), ECOG1912 (NCT02048813) and RESONATE-2 (NCT01722487). The analysis found that first-line ibrutinib-based treatment resulted in sustained efficacy with high progression-free survival (PFS) and overall survival (OS) rates in CLL patients with TP53 aberrations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

John Allan, MD, has done consultancy work, participated in advisory boards and/or received honoraria from Pharmacyclics, Janssen, Abbvie, BeiGene, Genentech and AstraZeneca; and has received research Funding from Genentech, Janssen and TG Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter